Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS1819-SD in Exocrine Pancreatic Insufficiency
NCT03481803Phase 2Completed
- Sponsor
- Entero Therapeutics, Inc.
- Start
- Jan 2017
- Primary completion
- Jun 2018
- Modality
- Replacement Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of adrulipase alfa in exocrine pancreatic insufficiency (EPI), sponsored by Entero Therapeutics, Inc.. Started Jan 2017; status: completed.
02
Drugs
adrulipase alfa
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT03481803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03481803.